Actively Recruiting
Evaluating Blood Biomarkers to Predict Outcomes in Adults with Polyneuropathy
Led by Rigshospitalet, Denmark · Updated on 2024-04-11
200
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are studying the use of blood biomarkers to predict the progression of polyneuropathy, a condition affecting the nerves. This observational prospective cohort study aims to understand how biomarkers measured at the start relate to disease severity over two years. The study is led by Rigshospitalet, Denmark, and involves 200 patients diagnosed with polyneuropathy. Participants will undergo physical tests, medical examinations, questionnaires, and blood biomarker assessments at the beginning of the study, then again at 1-year and 2-year follow-ups. The investigators will analyze how baseline biomarker levels and physical test results predict disease progression using statistical methods. During the study, participants will attend three assessment visits over two years where various tests and questionnaires will be completed. The main outcome measured is disease severity at 2 years, along with patient-reported outcomes. The study will also evaluate the accuracy of biomarkers and physical tests in forecasting disease progression.
CONDITIONS
Brief Title
Prognostic Value of Biomarkers in Polyneuropathy.
Research Team
T
Tina Dysgaard, Dr.med.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
